Schroder Investment Management Group Boosts Stock Position in Soleno Therapeutics, Inc. $SLNO

Schroder Investment Management Group raised its holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO) by 1,554.9% in the third quarter, Holdings Channel reports. The firm owned 280,296 shares of the company’s stock after purchasing an additional 263,359 shares during the period. Schroder Investment Management Group’s holdings in Soleno Therapeutics were worth $19,105,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Raymond James Financial Inc. bought a new stake in shares of Soleno Therapeutics during the 2nd quarter worth $25,000. Aster Capital Management DIFC Ltd bought a new position in Soleno Therapeutics during the third quarter valued at about $37,000. Osaic Holdings Inc. increased its holdings in Soleno Therapeutics by 97.7% during the second quarter. Osaic Holdings Inc. now owns 856 shares of the company’s stock worth $72,000 after buying an additional 423 shares during the last quarter. KBC Group NV purchased a new stake in Soleno Therapeutics during the second quarter worth about $77,000. Finally, Quantbot Technologies LP bought a new stake in Soleno Therapeutics in the third quarter worth about $67,000. 97.42% of the stock is owned by hedge funds and other institutional investors.

Soleno Therapeutics News Roundup

Here are the key news stories impacting Soleno Therapeutics this week:

• Neutral Sentiment: Numerous law firms are soliciting lead-plaintiff motions and reminding investors of a May 5, 2026 deadline to seek lead-plaintiff status; this concentrates filings and could determine the litigation’s direction but is a procedural development rather than a merits ruling. Soleno Therapeutics, Inc. (SLNO) Investors: May 5, 2026, Deadline in Securities Fraud Class Action Lawsuit – Contact Kessler Topaz Meltzer & Check, LLP
• Negative Sentiment: At least one class action alleges Soleno misled investors after reporting disappointing information on DCCR (VYKAT™ XR) related to the drug’s launch; these claims cite launch disruptions and could expose the company to damages and protracted litigation. Soleno Therapeutics (SLNO) Faces Securities Class Action Amid Hyperphagia Drug Launch Disruptions — Hagens Berman
• Negative Sentiment: Some filings and alerts include serious allegations about clinical-trial integrity (claims of “sham” trials and misrepresentations about safety/efficacy). If proven, such allegations increase regulatory scrutiny and settlement/defense costs. SLNO Lawsuit Alleges Allegedly Conducting Sham Clinical Trials – SueWallSt
• Negative Sentiment: Multiple firms (Rosen, Robbins, Faruqi, Levi & Korsinsky, Bronstein Gewirtz, and others) have announced investigations or cases covering the same March 26–Nov 4, 2025 class period, signaling broad coordinated investor litigation risk and likely continued headline-driven volatility and elevated trading volume. Soleno Therapeutics (SLNO) Faces Securities Class Action Amid Hyperphagia Drug Launch Disruptions – GlobeNewswire

Soleno Therapeutics Price Performance

Shares of NASDAQ:SLNO opened at $36.74 on Friday. The firm has a market capitalization of $1.90 billion, a PE ratio of 159.75 and a beta of -3.16. The company has a quick ratio of 5.55, a current ratio of 5.80 and a debt-to-equity ratio of 0.11. The company has a 50-day moving average price of $41.00 and a two-hundred day moving average price of $51.41. Soleno Therapeutics, Inc. has a twelve month low of $32.63 and a twelve month high of $90.32.

Soleno Therapeutics (NASDAQ:SLNO) last posted its quarterly earnings results on Wednesday, February 25th. The company reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.16. The business had revenue of $91.73 million during the quarter, compared to the consensus estimate of $88.55 million. Equities analysts forecast that Soleno Therapeutics, Inc. will post -3.72 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on SLNO. Wells Fargo & Company dropped their target price on shares of Soleno Therapeutics from $114.00 to $110.00 and set an “overweight” rating on the stock in a research note on Friday, February 27th. HC Wainwright lowered their price target on shares of Soleno Therapeutics from $120.00 to $100.00 and set a “buy” rating on the stock in a report on Wednesday, March 4th. Wolfe Research set a $60.00 price objective on Soleno Therapeutics in a research note on Monday, January 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Soleno Therapeutics in a report on Thursday, January 22nd. Finally, Robert W. Baird set a $107.00 target price on Soleno Therapeutics in a research report on Tuesday, January 13th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $106.85.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.